FDA says Homeopathic Family Medicine sells unapproved Cineraria Maritima Eye Drops for cataracts online.
What happened
FDA reviewed the company's website in May 2025 and found it offered Cineraria Maritima Eye Drops for sale in the United States. The website stated that the most common indication for the product is cataracts, which FDA used as evidence the product is intended as a drug. FDA determined the product is an unapproved new drug and that no FDA-approved application is in effect for it.
What FDA found
The website offers Cineraria Maritima Eye Drops with a claim that it treats cataracts, which shows the product is intended to treat disease and is therefore a drug.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The product is a new drug because it is not generally recognized as safe and effective for the claimed use.
FD&C Act section 201(p), 21 U.S.C. 321(p)There is no FDA-approved application for the product, so selling it violates the unapproved new drug provisions.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Labeling the product as a homeopathic drug does not exempt it from drug approval, adulteration, or misbranding requirements.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
Notify FDA in writing within fifteen working days of receipt of the letter of the specific steps taken to correct the violations, including an explanation and documentation, or state why correction cannot be completed and when it will be.
Who should pay attention
- online sellers of homeopathic products
- companies marketing eye drops with disease claims
- brands selling unapproved ophthalmic drug products
This is a summary. Read the original letter on fda.gov.